Neonatal immune challenge exacerbates experimental colitis in adult rats: potential role for TNF-alpha

Sarah J Spencer1, Niall P Hyland, Keith A Sharkey

  • 1Hotchkiss Brain Institute and Institute of Infection, Immunity, and Inflammation, Department of Physiology and Biophysics, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada. spences@ucalgary.ca

Insights

Neonatal exposure to lipopolysaccharide (LPS) exacerbates adult colitis severity, leading to increased tissue damage and inflammation. This effect is linked to elevated tumor necrosis factor-alpha (TNF-alpha) and not hypothalamic-pituitary-adrenal (HPA) axis activation.

Area of Science:

  • Immunology
  • Gastroenterology
  • Developmental Biology

Background:

  • Early life infections are linked to adult inflammatory bowel disease (IBD).
  • The specific impact of neonatal infection on colitis development and severity remains unclear.
  • Investigating neonatal immune challenges provides insight into long-term immune programming.

Purpose of the Study:

  • To determine the long-term consequences of neonatal lipopolysaccharide (LPS) exposure on colitis development in adult rats.
  • To assess the impact of juvenile LPS exposure as a comparison.
  • To evaluate associated changes in hypothalamic-pituitary-adrenal (HPA) axis activation and pro-inflammatory cytokine levels.

Main Methods:

  • Rats received LPS or saline on postnatal day 14 (neonatal) or day 28 (juvenile).
  • Adult rats were induced with 2,4,6-trinitrobenzenesulfonic acid (TNBS) to model colitis.
  • Colitis severity, weight loss, food intake, body temperature, plasma corticosterone, and TNF-alpha were measured.

Main Results:

  • Neonatal LPS exposure significantly worsened TNBS-induced colitis, increasing weight loss and tissue damage.
  • Neonatal LPS-treated rats exhibited hypothermia post-TNBS, unlike saline-treated controls.
  • Elevated TNF-alpha levels were observed in adult rats with neonatal LPS exposure, independent of HPA axis changes.

Conclusions:

  • Neonatal, but not juvenile, LPS exposure leads to persistent exacerbation of colitis in adulthood.
  • This exacerbation is associated with heightened TNF-alpha, suggesting an altered immune response.
  • The findings highlight the critical window of neonatal susceptibility to infection-induced immune dysregulation relevant to IBD.

Related Concept Videos

Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...